NEW YORK (GenomeWeb) – Raymond James today downgraded Genomic Health to Market Perform from Outperform, noting that the company's stock has essentially reached its prior price target with limited catalysts for positive near-term estimate revisions.

In a note to investors, analyst Nicholas Jansen said 2017 is shaking out to be more of a "transition" year than an "upside to numbers" year, with growth accelerants either already encapsulated by the price target or more likely to influence Genomic Health's revenues in 2018.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.